What Levam Treats: Main Uses and Benefits

Levam is considered relevant for managing conditions involving episodic or fluctuating manifestations, playing a role in symptomatic support across domains where additional symptomatic support is needed. The medicine is utilized to help with symptoms related to increased neurological or muscular activity and symptoms that become more disruptive during flare-ups.

Often used when symptoms intensify or become temporarily overwhelming, Levam may be part of symptomatic management. It helps address symptom clusters that interfere with daily functioning and contributes to improved comfort during periods of heightened symptoms. It is applied across clinical settings that involve acute or unstable symptom patterns, assisting with maintaining a sense of stability during difficult episodes. It provides supportive relief when symptoms create noticeable physiological strain.

Quick Fact: Used for Managing Symptoms Related to Heightened Physiological Activity

Who Can and Cannot Use Levam?

The population eligibility for Levam (Levamisole) is strictly defined by official regulatory documentation, focusing on absolute exclusions and populations requiring conditional use or caution.

---

Absolute Non-Eligibility (Contraindications)

Levam must not be used by patients with a known hypersensitivity or allergic reaction to Levamisole or any of its components. It is also strictly contraindicated in individuals with pre-existing blood disorders due to the risk of severe hematological reactions.

---

Populations Requiring Caution or Restriction

• Pregnancy and Lactation: Levam is generally not recommended for pregnant women (FDA Category C) or breastfeeding women, as there are no adequate studies in humans and use is only permitted if the potential benefit outweighs the potential risk.
• Organ Impairment: Patients with hepatic impairment (liver disease) or renal impairment (kidney disease) must use Levam with caution and monitoring. Use is not recommended in cases of severe kidney disease.
• Age Groups: The medicine has established use in adults. However, some regulatory sources indicate use in children is limited by a lack of specific comparative data across all contexts. Use in older adults is generally expected to be similar to younger adults.
• Comorbidities: Caution is advised for patients with a history of infection (as Levam may affect the immune response) and certain pre-existing conditions like Rheumatoid Arthritis.

Interactions with other medicines and products

Interaction scope

Classification	Detail (Official Regulatory Information Only)
Medicinal product categories	Anticoagulants, and medicines subject to metabolic inhibition.
Specific interacting medicines	Phenytoin, Phenobarbital, and Warfarin.
Mechanistic basis	Pharmacokinetic interaction due to metabolic inhibition; Pharmacodynamic potentiation; Disulfiram-like reaction (with alcohol).
Timing-based rules	None formally documented as mandatory time separation windows.
Population-specific notes	None explicitly documented in the interaction section of primary regulatory labels.
Interaction-related restrictions	Strictly prohibited combination with alcohol (ethanol).

---

Resulting interaction structure

Official interaction statements:

• Co-administration with alcohol is formally prohibited due to the risk of a severe, documented disulfiram-like reaction.
• Levamisole inhibits the clearance of certain co-administered medicines, resulting in a pharmacokinetic interaction that raises their plasma concentrations and overall exposure.
• Regulatory documents state that co-administration with phenytoin may result in its increased plasma levels due to metabolic inhibition.
• A pharmacodynamic interaction exists with anticoagulants, such as warfarin, which may potentiate the anticoagulant effect and lead to an increased risk of bleeding (elevated International Normalized Ratio or INR).
• The potential for increased plasma levels of phenobarbital is also noted in regulatory sources.

These official statements define Levam's interaction profile by documenting specific pharmacokinetic effects—metabolic inhibition leading to increased exposure—and critical pharmacodynamic effects, including potentiation of anticoagulation and a strictly prohibited substance-drug interaction with alcohol.

Levamisole: Dual Pharmacodynamic Mechanism

The biological action of Levamisole is defined by two distinct, independent mechanisms: a targeted effect on the parasite's neuromuscular system and an effect on the host's cellular immunity.

---

Selective Agonism at Parasitic Nicotinic Receptors

Levamisole’s primary anthelmintic action involves a specific interaction with unique nicotinic acetylcholine receptors (nAChRs) found on nematode muscle tissue. By acting as an agonist, the molecule rapidly and continuously depolarizes the muscle cell membranes. This initiates a physiological cascade that culminates in sustained spastic paralysis of the parasite. This molecular interference with the parasite's neuromuscular signaling results in its physical expelling.

---

Restoration of Depressed Host Cellular Immunity

Levamisole acts as a biological modulator, causing the restoration of function in specific host immune cells, such as T-lymphocytes and phagocytes. The molecule engages regulatory pathways to cause an increase in the activity of these cells and modify the production of cytokines (like IFN-gamma and IL-12), modifying the activity of depressed immune cells, restoring function in specific pathways of cellular immunity.

How to Use Levam: Official Administration Guidelines

This section describes the standardized approach to using Levamisole, detailing the administration routes, labeled dosing, and procedural instructions. The medicine's usage pattern varies significantly depending on the therapeutic application, utilizing either a single, short-term treatment or a defined, intermittent cycle.

---

Administration Scope and Dosage

Usage Type	Dosing Pattern	Frequency and Schedule
Anthelmintic	A single dose calculated at 2.5 mg/kg of body weight.	Single-dose administration, which may be repeated once after a seven-day interval for severe infections.
Immunomodulatory	An oral dose of 50 mg, administered multiple times per day.	Given for three consecutive days, followed by a 14-day interval before the next cycle begins.

The product is formulated for administration via the oral route (tablets and solutions) and the parenteral route (solution for injection), providing flexibility in the clinical setting. The anthelmintic dose requires accurate body weight estimation to ensure correct calculation and delivery.

---

Procedural Instructions

Certain instructions govern the practical use of the medicine. For the multi-day, cyclic regimen, if a dose is missed, the standard approach is to skip the missed dose and resume the regular schedule, with a strict directive against doubling a dose. Furthermore, specific formulations, such as concentrated oral solutions, require dissolution or dilution in a measured volume of water prior to intake to ensure proper concentration. The labeled instructions confirm that the medicine can be taken with or without food.

Levam: Recent Clinical Evidence

Research has primarily examined Levam’s activity against various parasitic nematodes, such as roundworms and hookworms. Studies in this area, which included randomized controlled trials (RCTs) involving adults and children, monitored the short-term change in parasitic load by measuring fecal egg count reduction (FECR) and rates of parasite expulsion. Findings describe patterns observed in these studies that informed the medicine’s inclusion on the World Health Organization's List of Essential Medicines.

Studies also explored Levam’s secondary role as an immunomodulator, primarily in children with frequent relapsing or steroid-dependent Nephrotic Syndrome. Trials were evaluated in these children to monitor outcomes such as the time until the first relapse and the overall frequency of relapses. Some trials described patterns where the measured relapse frequency was associated with the groups receiving Levam compared to control groups, and research also described patterns related to the cumulative steroid dosage that was administered during the study period.

Separately, Levam was studied for its potential use as an adjuvant therapy alongside chemotherapy (typically 5-FU) after surgery for high-risk colon carcinoma (Stage III). This research involved large, multi-center RCTs that examined long-term endpoints such as Overall Survival (OS) and Disease-Free Survival (DFS). These historical findings describe patterns that informed previous clinical guidance bodies, but the evidence is constrained by the historical nature of the study protocols and lacks comparison with contemporary regimens.

Beyond these areas, the immunomodulatory role was evaluated in small-scale, pilot studies across a wide range of other conditions. These studies explored varied endpoints, including immune markers and patient-reported outcomes. Findings were mixed and often inconsistent across different patient populations, suggesting that the evidence in these diverse areas is generally limited.

Research Gaps and Uncertainty

Evidence quality varies across studies, and long-term outcomes are not fully established beyond the intermediate follow-up periods observed in the main trials. Data for certain groups remain insufficient, particularly for the general elderly population, or in pregnant or nursing populations, where long-term research is limited. Subgroup findings are uncertain, and comparative evidence against modern standard treatments is often lacking.

Key Studies & References

1. LEVAMISOLE (Trade Name: Ergamisol®): Regulatory and Pharmacology Summary
2. Levamisole - Electronic Essential Medicines List (EML)
3. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children (Executive Summary)

Common questions about Levam (FAQ)

---

Q: How long does it typically take for Levam to start having an effect?

Levam is known to be rapidly absorbed into the body after administration. Studies and official information indicate that the concentration of the active substance in the blood typically reaches its peak within 1.5 to 2 hours. This rapid absorption time is consistent with its intended mechanism of action.

---

Q: Can Levam be taken with common over-the-counter pain relievers?

Regulatory documents advise caution when combining Levam with other medicines, as it is known to affect the metabolic breakdown (clearance) of certain drugs. Specific drug interaction resources list common pain relievers (e.g., acetaminophen) as potential interacting medicines. If any non-prescription medications are being used, this is information to share with a health care provider.

---

Q: How does Levam interact with alcohol consumption?

Co-administration of Levam and alcohol is formally prohibited due to the risk of a severe reaction known as a disulfiram-like reaction. This dangerous reaction is documented to cause symptoms such as flushing (a sudden reddening of the face), irregular heartbeat, low blood pressure, and sweating.

---

Q: Are there any long-term effects associated with using Levam?

Official safety documents, including those from European regulatory bodies, note the risk of severe, potentially long-lasting complications. These serious adverse events include agranulocytosis (a severe blood disorder) and leukoencephalopathy (a neurological condition), which are associated with its use, particularly in multi-day or long-term regimens.

---

Q: Can Levam affect my sleep patterns?

The official safety profile lists drowsiness, which is also called somnolence, as a common reaction. This effect is categorized as a nervous system disorder. If this effect occurs, official guidance suggests caution, as it may affect the ability to perform certain tasks.

---

Q: Why is it described that Levam can cause a metallic taste?

A metallic or bitter taste in the mouth is listed in the official safety profile as a reported side effect. This is one of the reactions commonly involving the gastrointestinal or nervous system that users may experience during treatment.

---

Q: Is Levam approved for use in children or adolescents?

Official documents note established use in adults. The medicine has also been studied and used in children for specific conditions, such as Nephrotic Syndrome. However, some regulatory sources indicate limitations on use in children due to a lack of specific comparative data across all contexts.

---

Q: Is Levam considered safe to use during pregnancy according to official sources?

Official safety information states that Levam is generally not recommended for pregnant women, and it has been assigned FDA Category C. This means that use is only permitted after a medical assessment determines that the potential benefit to the mother outweighs the potential risk to the unborn child.

---

Q: Is it normal to feel a bit nauseous when starting Levam?

Nausea and vomiting are listed in the official safety profile as common reactions, typically involving the gastrointestinal system. Since these are common effects, they are a known part of the medicine's safety profile when initiating treatment.

---

Q: How long after stopping Levam does the medicine stay in my system?

Levamisole is eliminated relatively quickly from the blood, with an elimination half-life of approximately 3 to 4 hours. However, the majority of the drug and its byproducts are excreted over three days.

---

Q: Is Levam a controlled substance or addictive in any way?

Regulatory bodies, including the DEA, classify Levamisole as Not a controlled drug under the Controlled Substances Act (CSA). The medicine does not carry a formal schedule classification for potential abuse.

---

Q: Is it true that Levam can cause skin sensitivity to sunlight?

The official safety profile lists skin rash as a common reaction. However, photosensitivity, or an increased sensitivity of the skin to sunlight, is not explicitly documented in the official adverse event lists.

---

Q: What should I know about Levam if I'm planning to drive or operate machinery?

The drug's safety profile includes nervous system disorders such as dizziness and drowsiness (somnolence) as common side effects. If these effects are experienced, it is noted that they have the potential to impair the ability to drive or operate complex machinery.

---

Q: Can Levam be taken if I am currently taking medication for high blood pressure?

Levamisole's interaction profile involves metabolic inhibition, meaning it can slow the breakdown of other medications. Specific drug interaction resources list certain high blood pressure medications (e.g., metoprolol) as potential interacting medicines, which should be shared with a health care provider.

---

Q: Can Levam be used during breastfeeding based on regulatory information?

Levam is generally not recommended for breastfeeding women according to official safety information. This is due to a lack of adequate human studies and is only permitted after a medical assessment determines that the potential benefit outweighs the potential risk to the nursing child.

---

Q: Can Levam interfere with the results of certain lab tests?

Levam is documented to affect a common group of enzymes called alkaline phosphatase, which are found in various body tissues. Because it is known to inhibit these enzymes, it may potentially interfere with certain laboratory tests that rely on the measurement of alkaline phosphatase activity.

---

Q: Why are people talking about Levam being used for 'X' condition (clarification needed)?

The medicine holds a distinct secondary classification as an immunomodulator, meaning it can affect the body's immune response. Due to this function, its use was evaluated in research for a wide range of other conditions beyond its primary purpose, including in past clinical trials as an adjuvant therapy in certain cancers.

How to Store and Dispose of Levamisole (Levam)

Official regulatory guidelines define specific storage and disposal requirements for Levamisole to maintain product integrity and ensure safety.

Storage Requirements

• Temperature: Store at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF). Excursions up to 30^circC are usually permitted.
• Protection: The medicine must be protected from light and kept in a dry, cool place.
• Container: Keep the product in its original container and ensure the container is tightly closed when not in use.
• Child Safety: It is mandatory to keep all medicines out of the sight and reach of children and to store the product locked up.

Disposal Instructions

• Disposal: Unused or expired Levamisole must not be disposed of in household waste or wastewater.
• Procedure: Contents and containers must be disposed of through an approved waste disposal plant or a drug take-back program, in accordance with local regulations.